Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population
N. Frost(Humboldt-Universität zu Berlin), Christian Grohé(DRK Kliniken Berlin), Antje Tessmer(Evangelische Lungenklinik Berlin), Norbert Suttorp(Humboldt-Universität zu Berlin), Jens Kollmeier(Helios Klinikum Emil von Behring), Alexander Schmittel(Franklin University), Maike de Wit(Florida Hospital Cancer Institute), Torsten Blum(MSB Medical School Berlin), D Misch(Helios Klinikum Emil von Behring), B. Schmidt(DRK Kliniken Berlin), Dennis Pultermann(Humboldt-Universität zu Berlin), Christian Grah(Gemeinschaftskrankenhaus Havelhöhe)
Cited by 3
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605